Nature Communications (Dec 2019)
An independent poor-prognosis subtype of breast cancer defined by a distinct tumor immune microenvironment
- Xavier Tekpli,
- Tonje Lien,
- Andreas Hagen Røssevold,
- Daniel Nebdal,
- Elin Borgen,
- Hege Oma Ohnstad,
- Jon Amund Kyte,
- Johan Vallon-Christersson,
- Marie Fongaard,
- Eldri Undlien Due,
- Lisa Gregusson Svartdal,
- My Anh Tu Sveli,
- Øystein Garred,
- OSBREAC,
- Arnoldo Frigessi,
- Kristine Kleivi Sahlberg,
- Therese Sørlie,
- Hege G. Russnes,
- Bjørn Naume,
- Vessela N. Kristensen
Affiliations
- Xavier Tekpli
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
- Tonje Lien
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
- Andreas Hagen Røssevold
- Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
- Daniel Nebdal
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
- Elin Borgen
- Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital
- Hege Oma Ohnstad
- Department of Oncology, Division of Cancer Medicine, Oslo University Hospital
- Jon Amund Kyte
- Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital
- Johan Vallon-Christersson
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Faculty of Medicine, Lund University
- Marie Fongaard
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
- Eldri Undlien Due
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
- Lisa Gregusson Svartdal
- Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital
- My Anh Tu Sveli
- Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital
- Øystein Garred
- Department of Pathology, Division of Laboratory Medicine, Oslo University Hospital
- OSBREAC
- Arnoldo Frigessi
- Department of Biostatistics, Oslo Centre for Biostatistics and Epidemiology, University of Oslo and Research Support Services, Oslo University Hospital
- Kristine Kleivi Sahlberg
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
- Therese Sørlie
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
- Hege G. Russnes
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
- Bjørn Naume
- Department of Oncology, Division of Cancer Medicine, Oslo University Hospital
- Vessela N. Kristensen
- Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital
- DOI
- https://doi.org/10.1038/s41467-019-13329-5
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 14
Abstract
In breast cancer, the immune infiltration of the tumour associates with clinical outcome. Here, the authors infer immune context based on gene expression data and identify a new independent subtype linked to pro-tumorigenic immune infiltration.
